key: cord-0846083-dffxuogi
authors: Nandavaram, S.; Scheuble, V.; Benninger, L.; Chandrashekaran, S.
title: Short Term Outcomes of Patients Who Underwent Lung Transplant for COVID-19 ARDS
date: 2022-04-30
journal: The Journal of Heart and Lung Transplantation
DOI: 10.1016/j.healun.2022.01.1336
sha: 6ea90a849b4893b10260cb535c7743055c7e4db0
doc_id: 846083
cord_uid: dffxuogi

Purpose Lung transplantation is a life saving treatment option for patients with COVID-19 ARDS. We aim to assess the short-term outcomes of patients who underwent lung transplantation for COVID ARDS. Methods This is a single-center retrospective cohort study of patients who underwent lung transplantation for COVID 19 ARDS between 7/1/2020 and 06/30/2021. Study was IRB-approved. Baseline demographic data, pre transplant variables, peri operative data and post transplant variables were extracted. Post-transplant graft function variables were followed until 09/30/2021. Results Twenty patients underwent lung transplantation alone, and one patient underwent lung kidney transplantation. Nineteen patients (90%) were ECMO bridge to transplant and twenty patients (95%) were on mechanical ventilator until the transplant. These patients were followed for a median of 234 days [IQR (188-339)]. Three patients (14%) completed a one-year follow-up. Eighteen patients (86%) completed six months follow-up. None of the patients required dialysis. At the end of the follow up period, all patients have good graft function and none of the patients are on supplemental oxygen. Conclusion With careful selection, lung transplants can be performed with reasonable post-transplant outcomes in COVID 19 ARDS patients. However, these patients tend to have a prolonged post transplant hospital stay, a median of 48 days with IQR (28.5 - 73.5). 50% of patients had at least one return to operating room post transplant for hemothorax.

patients, who were not included in the present analysis, but had been presumably affected by an asymptomatic/mild form of the disease. Conclusion: Apart from immunosuppression, the majority of our patients presented at least one risk factor for mortality in COVID-19 (diabetes, chronic kidney disease, arterial hypertension) and, for this reason, we felt that they should be hospitalized to enable close monitoring and prompt management of possible complications and deterioration. Clinical course seemed favorable in only two thirds of our patients but, for the time being, none of these individuals showed sign of new-onset CLAD after COVID19. Purpose: Lung transplant (LTx) recipients have increased risk of infection with SARS-CoV-2 and have reduced efficacy from COVID-19 vaccination. The Delta variant of SARS-CoV-2 has increased virulence compared to earlier variants. We hypothesized that LTx recipients would have increased susceptibility to Delta variant infection despite vaccination. Methods: We performed a retrospective cohort study of 314 LTx recipients followed between 1/1/2020-9/30/2021. Diagnosis of SARS-CoV-2 infection by PCR was recorded; Delta variant comprised >99% of strains from 6/1/2021-9/30/2021. Data regarding COVID-19 vaccination status, symptom development, hospitalization, intubation, and death were collected. Results: Forty-four patients (14%) were diagnosed with COVID-19, 18 (41%) of which were Delta variant. The rate of infection with Delta was 4fold higher than with earlier strains (Figure, 0.016 vs. 0.004 cases / patient months, p<0.001). Fifteen (83%) patients diagnosed with Delta variant were fully vaccinated at the time of infection (p<0.001). The rate of infection with Delta variant in vaccinated and unvaccinated individuals was similar (0.017/patient months with vaccine, 0.015/patient months without vaccine, p=0.84). The majority (>89%) of patients had respiratory symptoms in both groups. More patients with Delta variant received monoclonal antibody infusions (89% vs. 54%, p=0.021) and fewer patients with Delta variant had resolution of disease (50% vs. 92%, p<0.001). There was a trend towards greater O 2 needs with Delta variant (p=0.07). Hospitalization (38% vs. 23%), intubation (11% vs. 4%), and death (11% vs. 4%) were numerically greater with Delta variant, although not statistically significant. Conclusion: The incidence rate of SARS-CoV-2 infection was significantly greater with Delta variant in LTx recipients, despite high prevalence of full vaccination during the Delta wave. Further study in larger cohorts is needed to determine whether booster vaccines can reduce such infectivity. Purpose: The post lung transplant (LTx) rehabilitation program was required to rapidly reduce service provision during coronavirus (COVID 19) pandemic. This was achieved by minimising the group format, number of sessions and type of exercises performed, as it transitioned from a centre-based supervised program to a home based program. Aim: This retrospective study aimed to compare standardised outcome measures for LTx recipients from the non-COVID era (2019) to those from LTx recipients who completed rehabilitation at home during the COVID (2020). Study population included post LTx males & females > 18 years who underwent BSLTx or SLTx at The Alfred from March to August 2020, compared to a matched cohort transplanted between March-August in 2019. Methods: The 2019 post LTx rehabilitation program was a thrice weekly, 8 weekly supervised, group format consisting of 30 minutes cardiovascular training on treadmill and exercise bike plus resistance training for upper and lower limbs. During 2020 (COVID) the rehabilitation program was shortened to a twice weekly, individual, 2 -3 week format followed by a home exercise program (HEP) using exercise diary and weekly phone follow up. COVID era patients were discharged from the gym to the HEP as soon as they were safe to exercise independently. Outcome measures -six minute walk test (6MWT), grip strength (GS) on a dynamometer and a sit to stand test in one minute (STS) were taken on entry to the rehabilitation program and three months post (3/12P). Quality of life (QOL) questionnaire was completed. Results: Groups were well matched for LTx age, surgery and length of hospital stay. After 3 months, COVID era participants had not significantly increased 6MWD compared to Non -COVID era (-183m (-230 to -137)) STS improved significantly in both Non-COVID (p=0.001) and COVID (p=0.008) . There was no improvement in QOL or GS for COVID group, but significant improvements for non-COVID QOL (p=0.001) and GS (p=0.05). Conclusion: The change to a HEP in COVID era may have negatively impacted the improvement in functional exercise capacity, GS and QOL for those LTx recipients. Further research is required to develop an optimal HEP model. Purpose: Immunization is heralded as a key tool to combat the COVID-19 pandemic. One key technology, messenger RNA (mRNA) vaccines have demonstrated an efficacy greater than 94% 1,2 . While mRNA vaccines create strong protection in the majority of patients, the antibody response in solid organ recipients has been reported to be less reliable 3 . Herein, we report the incidence and mortality of COVID-19 in lung transplant recipients after receiving a messenger RNA vaccine (BNT162b2 [Pfizer-BioN-Tech] or mRNA1273 [Moderna]).

Methods: From February 1, 2021 to September 1, 2021, SARS-CoV-2 positivity, admissions to the hospital, and mortality among lung transplant recipients was recorded at our institution. This timeframe was selected as the mRNA vaccine became available to recipients of lung transplantation in February of 2021. To obtain the immunization status of lung transplant recipients eligible for vaccination with one of the two mRNA vaccines, a query of the electronic medical record was performed during the previously mentioned dates. Results: Among 317 patients, 276 had received at least two doses of mRNA vaccine (87%). Twenty-six tested positive (8.2%). Of the 26 individuals who developed COVID-19, 20 (76.9%) required admission to the hospital with eight deaths (30.8%). Four deaths occurred among the 13 individuals who contracted SARS-CoV-2 despite having received a minimum of two doses of mRNA vaccine representing a 30.7% mortality. The average duration between immunization and a positive PCR result was 86 days (SD 56 days) for individuals who had received at least two doses of a vaccine. Conclusion: Recent studies have shown that a third dose of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) can augment the antibody response in solid organ transplantation recipients 4 . The immunogenicity of the mRNA vaccine in this population still remains less vigorous compared to the immunocompetent. The reduced efficacy of mRNA vaccines combined with the elevated rate of admission and mortality described above, demonstrate that vaccination alone cannot annul the impact of COVID-19 in these patients. When mask wearing, social distancing, and hand-washing fail, therapies such as casirivimab and imdevimab (REGN-COV2), neutralizing monoclonal antibodies against SARS-CoV-2 could be considered in early disease to suppress viral load 5 and protect this vulnerable population despite immunization status.

(1313)

Recipients: A Single Centre Study U. Shah, 1 V. Rahulan, 2 S. Ravipati, 2 S. Kumar, 2 A. Kamath, 2 S. Kori, 2 S. Panda, 2 P. Kumar, 2 P. John, 2 M. BN, 2 P. Dutta, 2 and S. Attawar. 2 1 Pulmonology, KIMS, Hyderabad, India; and the 2 KIMS, Hyderabad, India.

Purpose: Solid Organ Transplant recipients (SOT) are at higher risk of SARS-CoV-2 infection. Mortality rates reported between 13 to over 30% in SOT recipients. SARSÀCoVÀ2 vaccination may help reduce the morbidity and mortality of COVIDÀ19 among SOT. There is paucity of literature of SARS-CoV-2 vaccination efficacy in lung transplantation recipients . The purpose of the study was 1) to evaluate SARS-CoV-2 vaccination efficacy & safety in lung transplantation recipients and 2) to assess the need for 3 rd booster dose. Methods: A retrospective study (from Jan 2021 till Oct 2021) of lung transplantation recipients receiving 2 doses of SARS-CoV-2 vaccination available in India i.e. ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) or Whole-Virion Inactivated Vero Cell vaccine, was done to evaluate vaccination efficacy and safety. SARS-CoV-2 spike COVID antibodies levels were checked 4 weeks after 2 nd dose of vaccination. Local and Systemic reactions to vaccination were noted Results: 11 Bilateral lung transplantation recipients and 4 Combined Heart-Lung transplantation recipients received SARS-CoV-2 vaccination. Out of 15 recipients, 11 recipients received ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) and 4 recipients received Whole-Virion Inactivated Vero Cell vaccine. 12 recipients developed mild pain at vaccination site, 2 recipients developed local tenderness and 1 recipient developed redness at vaccination site as part of local reaction . 5 recipients developed fever, 5 recipients experienced fatigue/bodypain, 2 recipients had vomiting, 2 recipients experienced headache & 1 recipient developed abdominal pain as part of systemic reactions. 8 (53.3%) out of 15 recipients developed significant SARS-CoV-2 spike antibodies level demonstrating vaccination efficacy. 7 (46.6%) recipients demonstrated lower SARS-CoV-2 antibodies titre (Less than cut off values) indicating no significant vaccination efficacy. 1 recipient developed vaccine breakthrough mild infection after 2 nd dose. Conclusion: Our experience has shown that SARS-CoV-2 vaccination efficacy was demonstrated in nearly 50 % of lung transplantation recipients.

The study also showed safety of SARS-CoV-2 vaccines in such immunocompromised subset. However, for those recipients with no vaccination efficacy, utility of 3 rd booster dose and at what interval needs more research.

The purpose of this study was to understand impact of infection with COVID-19 in this population, to investigate different variables that contributed to the prognosis, and to assess the long-term clinical outcomes. This represents the largest cohort of continuously followed LTR with COVID-19 to date. Methods: We conducted an observational retrospective cohort study of LTRs infected with COVID 19 at a major transplant center between

2%) patients had at least one dose of mRNA COVID vaccine. 29 (54.7%) patients were treated as outpatient. Among admitted patients, 13 (24.5%) were treated in the ICU, and 7 (13.2%) required mechanical ventilation. Mortality rate was 15.1%. 26 patients had follow up on their FEV1 in 3 months, 33 in 6 months, and 7 up to 12 months. 14 (26.4%) patients had at least >10% drop in their FEV1, of which 10 patients had >20% drop. 18 patients had TBLB in 3 months, 19 in 6 months

Conclusion: Out of our 53 LTR with COVID infection, 24.5% had severe disease. Mortality was high in our cohort at 15.1%. PFT decline was common, with 26.4% having an FEV1 drop of over 10% at follow up

Short Term Outcomes of Patients Who Underwent Lung Transplant for COVID-19 ARDS S. Nandavaram, 1 V. Scheuble, 2 L. Benninger, 3 and S

Methods: This is a single-center retrospective cohort study of patients who underwent lung transplantation for COVID 19 ARDS between 7/1/2020 and 06/30/2021. Study was IRB-approved. Baseline demographic data, pre transplant variables, peri operative data and post transplant variables were extracted. Post-transplant graft function variables were followed until 09/30/2021. Results: Twenty patients underwent lung transplantation alone